Weisman, A., Bai, J
Unlike full-length growth hormone, AOD-9604 does not bind to the classical hGH receptor, does not elevate IGF-1 levels, and does not impair insulin sensitivity or glucose tolerance
State Legislative Landscape in 2025 Despite a significant number of bills in 2023 and 2024 that would have required mandated coverage of GLP-1s in Medicaid, state employee health plans, or for health insurers regulated by the state, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas have introduced legislation mandating coverage in 2025 to date
Khera R, Haimovich J, Hurley NC, McNamara R, Spertus JA, Desai N, Rumsfeld JS, Masoudi FA, Huang C, Normand SL, Mortazavi BJ, Krumholz HM